Status:

COMPLETED

Phase IIa Safety and Efficacy Study of SPP635 in Mild to Moderate Hypertension

Lead Sponsor:

Speedel Pharma Ltd.

Conditions:

Hypertension

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

Brief Summary

This study is conducted to investigate the effect of the oral renin inhibitor SPP635 on blood pressure in patients with mild to moderate hypertension.

Detailed Description

Renin-Angiotensin system blockade is a well established target for treatment of high blood pressure. Blocking the system at the initial step, however, is a rather new concept that could only be implem...

Eligibility Criteria

Inclusion

  • male or female patients with mild to moderate hypertension

Exclusion

  • female patients of child-bearing potential or breast-feeding

Key Trial Info

Start Date :

October 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2007

Estimated Enrollment :

35 Patients enrolled

Trial Details

Trial ID

NCT00376636

Start Date

October 1 2006

End Date

May 1 2007

Last Update

October 30 2007

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

IKP Bobenheim GmbH

Mannheim, Germany, 68167

Phase IIa Safety and Efficacy Study of SPP635 in Mild to Moderate Hypertension | DecenTrialz